

1 **Title:** Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle
2 Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older

3 **Authors:** Philippe Gobeil¹, Stéphane Pillet¹, Annie Séguin¹, Iohann Boulay¹, Asif Mahmood¹,
4 Donald C Vinh², Nathalie Charland¹, Philippe Boutet³, François Roman³, Robbert Van Der
5 Most⁴, Maria de los Angeles Ceregado Perez³, Brian J Ward^{1,2†}, Nathalie Landry^{1†}

6 **Affiliations:** ¹ Medicago Inc., 1020 route de l'Église office 600, Québec, QC, Canada, G1V
7 3V9; ² Research Institute of the McGill University Health Centre, 1001 Decarie St, Montreal,
8 QC H4A 3J1; ³ GlaxoSmithKline Biologicals SA (Vaccines), Avenue Fleming 20, 1300 Wavre,
9 Belgium; ⁴ GlaxoSmithKline Biologicals SA (Vaccines), rue de l'Institut 89, 1330 Rixensart,
10 Belgium; [†] These individuals are equally credited as senior authors.

11 * *Corresponding author:* Nathalie Landry, 1020 Route de l'Église, Bureau 600, Québec, Qc,
12 Canada, G1V 3V9; Tel. 418 658 9393; Fax. 418 658 6699; landryn@medicago.com

13 **Abstract**

14 The rapid spread of SARS-CoV-2 globally continues to impact humanity on a global scale with
15 rising morbidity and mortality. Despite the development of multiple effective vaccines, new
16 vaccines continue to be required to supply ongoing demand. We report Day 42 interim safety
17 and immunogenicity data from a Phase 2, randomized, placebo-controlled trial in Adults aged
18 18+ immunized with a virus-like particle vaccine candidate produced in plants displaying
19 SARS-CoV-2 spike glycoprotein (CoVLP) adjuvanted with AS03 (NCT04636697). This
20 report focuses on presenting safety, tolerability and immunogenicity, as measured by
21 neutralizing antibody (NAb) and cell mediated immunity (IFN- γ and IL-4 ELISpot) responses,
22 in Adults aged 18-64 (Adults) and Older Adults aged 65+ (Older Adults). CoVLP adjuvanted
23 with AS03 was well-tolerated and adverse events (AE) were primarily mild or moderate and of
24 transient duration. AEs in Older Adults were more limited than those observed in the Adult
25 population. CoVLP with AS03 induced a significant humoral immune response in both age
26 cohorts. CoVLP with AS03 induced a greater humoral response in Adults than Older Adults
27 after a single dose but this effect was overcome with a second dose when both age cohorts
28 responded with NAb titers that were ~10-fold higher than those in a panel of sera from patients
29 recovering from COVID-19. A single dose of CoVLP with AS03 induced a significant IFN- γ
30 response in both age cohorts; a second dose significantly boosted IFN- γ and IL-4 responses in
31 both age cohorts. Adults generated a stronger IFN- γ and IL-4 cellular response than did Older
32 Adults after one or two doses of AS03-adjuvanted CoVLP. Safety and immunogenicity from
33 Adults with comorbidities as well as final safety and immunogenicity responses after 12
34 months will be reported upon availability.

35 **Keywords:** SARS-CoV-2, Covid-19 vaccine, virus-like particles, *Nicotiana benthamiana*,
36 *Agrobacterium tumefaciens*, safety and immunogenicity, neutralizing antibodies, cell-mediated
37 immunity.

38 Introduction

39 Following a cluster of pneumonia cases in the city of Wuhan in Hubei province of China in
40 December 2019¹, a novel coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2
41 [SARSCoV-2]) was identified as the causative agent. The disease was subsequently named
42 ‘coronavirus disease 2019’, or COVID-19^{1,2}. The rapid international spread of COVID-19
43 prompted the World Health Organization (WHO) to declare a pandemic in March 2020³. As
44 of May 6th, there has been more than 150 million cases of COVID-19 and >3.2 million deaths⁴.
45 This public health emergency sparked a remarkable global effort to develop vaccines using a
46 wide range of traditional and novel platforms including messenger ribonucleic acid (mRNA),
47 deoxyribonucleic acid (DNA), inactivated virus, live viral vectors, recombinant proteins,
48 peptides, or virus-like particles (VLPs)^{5,6}. At the time of writing, >60 of these vaccines have
49 entered clinical testing and at least 14 of them have been authorized for use in at least one
50 country. Despite these successes, there remains an urgent global need to approve and distribute
51 further safe and effective vaccines⁷.

52 While it is now clear that humoral immunity is highly correlated with protection⁸, both innate⁹⁻
53 ¹² and cellular immunity make significant contributions to lasting protection against SARS-
54 CoV-2 infection. Passive antibody transfer has proven protective in both non-human primate
55 animal models and in the therapeutic treatment of patients¹³⁻¹⁵. Correlates of protection have
56 recently been proposed for both binding and neutralizing antibody titers^{8,16}. Similarly, a clear
57 role for cell-mediated immunity has been suggested for viral clearance and prevention of
58 serious disease, as well as for long-term immunity^{14,17-19}. Optimally, SARS-CoV-2 specific
59 vaccines should provide a well-coordinated response involving multiple elements of the
60 immune system.

61 The vaccine candidate developed by Medicago, a Coronavirus-like particle (CoVLP), is a self-
62 assembling VLP that displays trimers of recombinant S protein of SARSCoV2 embedded into
63 the lipid bilayer of the nanoparticles. These VLPs are produced in a plant (*Nicotiana*
64 *benthamiana*) and closely resemble the native structure of SARS-CoV-2 viruses^{20,21}. These
65 plant-produced VLPs lack viral genetic material and can be stored at 2 – 8 °C. Medicago’s
66 vaccine is administered with the oil-in-water Adjuvant System 03 (AS03)²². The AS03 initiates
67 a transient innate immune response at the injection site and draining lymph node in animal
68 models^{23,24} and in human peripheral blood^{10,25,26}. That innate immune response potentiates and
69 shapes the adaptive immune response to the vaccine antigen including both antibody and T-cell
70 responses, resulting in increased response magnitude, breadth, durability, and antibody avidity

71 ²⁷⁻²⁹. AS03 has been used in the licensed pandemic A/H1N1pdm09 influenza vaccines
72 Arepanrix H1N1 (in Canada) and Pandemrix (in Europe), of which 90 million doses have been
73 administered worldwide, as well as in other licensed (Q Pan H5N1 in the USA) or vaccine
74 candidates ³⁰. In Medicago's Phase 1 study, AS03 significantly enhanced both cellular and
75 humoral responses to CoVLPs and the vaccine had an acceptable safety profile ²¹.
76 Herein we report interim results of the Phase 2 portion of an on-going Phase 2/3 randomized,
77 placebo-controlled study conducted at multiple sites in Canada and the USA. The Phase 2
78 portion of this study was designed to confirm the chosen formulation and dosing regimen (2
79 doses of 3.75 µg CoVLP adjuvanted with AS03 given 21 days apart: hereafter CoVLP+AS03)
80 in adults ≥18 years of age. This report includes responses in healthy adults aged 18-64
81 (Population #1: "Adults") and in older adults aged 65 years and older (Population #2: "Older
82 Adults"). Analysis of the Phase 2 data for Population #3 ("Adults with Comorbidities") is
83 underway and will be released once available. Assessment of the efficacy of CoVLP+AS03 in
84 all three adult Populations is currently on-going in the global, Phase 3 portion of the study.

85

86 **Results**

87 *Demographic and baseline clinical characteristics*

88 Subjects were screened for SARS-CoV-2 antibodies using a commercial ELISA that targets the
89 nucleocapsid protein (although both seronegative and seropositive subjects were enrolled) and
90 randomized 5:1 to receive CoVLP+AS03 or placebo (saline).

91 Participant demographics are presented in Table 1 and subject disposition is presented in Figure
92 1. The mean ages in Population 1(Adults), were 43.7 years and 42.4 years in vaccinated and
93 placebo groups, respectively. The mean ages in Population 2 (Older Adults), were 71.1 years
94 and 71.7 years in vaccinated and placebo groups, respectively. In all groups, subjects were
95 mostly White or Caucasian (96.7% in Adults, 98.6% in Older Adults). Subject in the Adult and
96 Older Adult populations self-identified as Hispanic or Latino (2.9% and 1.8%), Asian (2.0%
97 and 1.1%) or Black or African American (1.0% or 0%) respectively. Eleven countries are
98 planned for the Phase 3 portion of the Phase 2/3 study to include a more diverse population
99 than that recruited in Phase 2.

100 306 Adults and 282 Older Adults were enrolled in the study. Of the 588 subjects who received
101 a first dose of vaccine, 573 (97.4%) also received their second dose.

102

103 *Safety*

104 Safety and tolerability data after the first and second doses (as of April 2, 2021) are provided
105 for 306 and 301 subjects in the Adult and for 282 and 272 in the Older Adult groups
106 respectively. Overall, the vaccine was well-tolerated in both populations, with a slightly milder
107 reactogenicity profile in the Older Adults.

108 Reactogenicity is illustrated in Figure 2 for solicited A) local and B) systemic AE. Frequency
109 of solicited AE increased after the second dose relative to the first dose in both age cohorts
110 although Older Adults generally had more muted responses than Adults: 94.5% and 88.4% of
111 Adults reported at least one local AE after the first and second doses respectively compared to
112 61.7% and 54.2% of the Older Adults. In both study populations after the second dose, pain at
113 the injection site was the most frequently reported local AE (89.3% of Adults and 72.8% of
114 Older Adults) while fatigue (67.6% of Adults and 46.1% of Older Adults) and muscle aches
115 (66.0% of Adults and 43.0% of Older Adults) were the most frequently reported systemic AEs.

116 In both populations, the majority of AEs were mild (Grade 1) or moderate (Grade 2) in severity
117 (2.1% and 6.3% of Adults experienced grade 3 AEs after the first and second doses respectively
118 while in Older Adults 0% and 8.7% of participants experienced grade 3 AEs after the first and
119 second doses) and transient, typically resolving within 24 hours to 3 days. No Grade 4 AEs
120 were reported in either study population. No clinically significant laboratory abnormalities,
121 related serious AEs, or cases of Vaccine-Associated Enhanced Disease (VAED), anaphylaxis,
122 or potential immune-mediated disorders monitored as Adverse Events of Special Interest
123 (AESI) have been reported. No pregnancies have been reported to date.

124

125 *Immunogenicity: Antibody Response*

126 Pseudovirion neutralizing antibody (NAb) responses (based on a data cut-off of April 9th, 2021)
127 are illustrated in Figure 3. Relative to both pre-vaccine sera (Baseline) and placebo controls,
128 significant increases were observed in GMTs in both age cohorts at 21 days (D21) after the first
129 dose with further significant increases 21 days after the second dose (D42).

130 A single dose of CoVLP+AS03 induced a four-fold rise in NAb in a larger proportion of the
131 Adults (51.3%, 95CI: 44.7- 57.7) relative to Older Adults (39.6%, 95CI: 32.8- 46.7, $p=0.017$),
132 an effect also reflected in the D21 GMTs (44.1%, 95CI: 35.7- 54.6 in Adults and 31.1%, 95CI:

133 24.7- 39.1 in Older Adults, $p<0.001$). This difference between the two age cohorts disappeared
134 with the second dose of CoVLP+AS03 and GMTs were not significantly different at D42
135 (2027, 95CI: 1749- 2350 for Adults and 1956, 95CI: 1526- 2509 in Older Adults, $p=0.797$).
136 The seroconversion rates were also comparable between the two age cohorts at D42 (99.2%,
137 95CI: 97.0- 99.9 in Adults and 97.7%, 95CI: 93.4- 99.5 in Older Adults, $p=0.348$).

138 Consistent with observations from the Phase 1 study, the NAb titers elicited by CoVLP+AS03
139 at D42 were approximately 10-fold higher than those observed in a panel of convalescent sera
140 (10.2x in Adults and 9.8x in Older Adults).

141 To assist in standardizing the NAb results, the WHO pooled plasma reference standard 20/136,
142 was included in the pseudovirion NAb assay yielding a reference GMT value of 1872.

143 Expressing the GMT results in International Units (IU/mL), the Adults in our Phase 2 study had
144 NAb values of 23.6 and 1083 IU/mL and the Older Adults had values of 16.6 and 1045 IU/mL
145 after the 1st and 2nd doses respectively.

146 Prior to vaccination, 9 (1.5%) of the subjects the Phase 2 portion of the study were seropositive
147 at Baseline (6 Adult and 3 Older Adults); all received CoVLP+AS03. At D21, their NAb GMTs
148 were significantly increased in all groups (5756 at D21 relative to 63.9 at D0 in Adults and
149 4909 at D21 relative to 49.6 at D0 in Older Adults). A second dose was only moderately
150 effective in further increasing NAb titers in Older Adults (5786 at D42 in Adults and 10400 at
151 D42 in Older Adults). These data illustrate the potential for CoVLP+AS03 to boost the NAb
152 response even in those presumed to have had prior infection.

153 Overall, CoVLP +AS03 induced comparable NAb responses in both age cohorts. Although
154 small differences between the groups were observed at D21 after the first dose, these
155 differences were overcome by the second dose.

156

157 *Immunogenicity: Cell Mediated Response*

158 Th₁- and Th₂-type cellular responses were assessed by IFN- γ and IL-4 ELISpots in peripheral
159 blood mononuclear cells (PBMC) restimulated with a spike protein peptide pool (Figure 3).
160 These interim data reflect a data cut-off of April 16th, 2021.

161 As observed in the Phase 1 study of CoVLP+AS03²¹ and previously reported in several studies
162^{31,32}, a significant minority (~20%) of individuals were observed to have pre-existing (D0) IFN-
163 γ responses to the spike protein. There was no relationship between NAb seropositivity and

164 IFN- γ responses at baseline. In both age cohorts, vaccination with CoVLP+AS03 induced a
165 significant increase in IFN- γ response at D21 which was further significantly increased after a
166 second dose at D42 (Figure 3A). Adults had a significantly greater IFN- γ response relative to
167 Older Adults at both D21 ($p < 0.0001$) and D42 ($p < 0.0001$). Sixty-nine percent of the Adults
168 and 51% of Older Adults displayed a detectable IFN- γ response after one dose (D21). The
169 frequencies of responders eliciting a detectable response increased to 96% and 86% after the
170 second dose in Adults and Older Adults respectively.

171 Also consistent with the results from the Phase 1 study, no subject in either group had a
172 measurable IL-4 response pre-vaccination (D0). While a limited portion of subjects responded
173 to CoVLP+AS03 with a detectable IL-4 response after one dose (35% in Adults and 17% in
174 Older Adults), the proportion of ‘responders’ increased to 94% and 75% after the second dose
175 of CoVLP+AS03 in Adults and Older Adults respectively. Although the second dose of
176 CoVLP+AS03 significantly increased the response in both populations, the Adults had median
177 counts significantly higher than Older Adults ($p=0.0002$).

178

179 *Discussion*

180 The Phase 2 portion of the ongoing Phase 2/3 study of CoVLP+AS03 was designed to confirm
181 the selection of CoVLP dose and adjuvant identified in the Phase 1 trial and to assess the
182 performance of the chosen formulation in both adults aged 65 or less in good health, adults 65
183 years and more, and adults with comorbid conditions that put them at increased risk from
184 COVID-19. This interim report focuses on healthy individuals ≥ 18 years of age. The data for
185 individuals with comorbidities are being compiled and will be released in a separate
186 manuscript. The primary outcomes for the Phase 2 portion of this study focused on short-term
187 (up to D42) safety and tolerability of CoVLP+AS03 and the ability of this novel candidate to
188 induce both NAb and cellular responses to SARS-COV-2 spike protein.

189 Reactogenicity in Adults in the Phase 2 study confirmed the profile observed in the much
190 smaller Phase 1 study in 18–55-year-old adults that received CoVLP(3.75 μ g) with AS03
191 ($n=20$). Local reactogenicity was characterized by injection site pain in most subjects while
192 systemically, reactogenicity was characterized by muscle aches, fatigue, and/or headache in
193 approximately 60% of the study participants. There was a trend towards increased local and
194 systemic reactogenicity after the second dose, although almost all reported AEs were mild-to-

195 moderate and transient in nature. Although only the 3.75 µg dose level of CoVLP was used in
196 the Phase 2 study, data from the Phase 1 trial that included groups given unadjuvanted CoVLP
197 at three dose levels (3.75, 7.5 and 15µg/dose) showed that local and systemic reactogenicity
198 was higher in adjuvanted groups as compared to non-adjuvanted groups, as would be expected
199 from its use with other antigens^{25,33,34}. As expected²⁶ and has been observed for mRNA,
200 adenovirus vector, inactivated virus, and recombinant protein-based COVID-19 vaccines³⁵⁻⁴²
201 reduced reactogenicity was observed in the older adults. The safety profile in the Older Adults
202 was consistent with the safety profile in the Adult population no new safety concerns were
203 reported relative to our phase 1 study, suggesting that CoVLP+AS03 is well-tolerated in
204 healthy individuals 18 years of age and older.

205 Both the humoral and cellular immune responses seen in the Phase 2 study confirmed the
206 robust immunogenicity results documented in the 18-55 year old healthy adults during the
207 Phase 1 study²¹ as well as extending these observations to older adults. After two doses of
208 CoVLP+AS03, seroconversion occurred in >99% of the subjects and NAb titers were ~10x
209 higher than those observed in convalescent sera. Although the NAb response after the first dose
210 of CoVLP+AS03 was slightly weaker in the Older Adult population than in the Adults, the
211 differences in seroconversion rate and GMTs between the two age cohorts disappeared after the
212 second dose. This observation is consistent with the generally reduced capacity of older
213 individuals to respond to vaccination and with findings for other SARS-CoV-2 vaccines⁴²⁻⁴⁴.
214 The decreased ability of even healthy older individuals to mount strong immune responses after
215 vaccination is likely multi-factorial including a general decline in immune function (ie:
216 immunosenescence) and chronic low-level inflammation (so-called ‘inflammaging’)⁴⁵.
217 Consistent with the observations that adjuvants can enhance vaccine-induced responses in older
218 individuals⁴⁶, these results suggest that two-doses of CoVLP+AS03 can overcome these age-
219 associated limitations for NAb production at least.

220 The number of Adult or Older Adult subjects in the current study with pre-existing NAb titers
221 to SARS-CoV-2 was very low (n=9, 1.5%) but vaccination with CoVLP+AS03 nonetheless
222 appeared to induce a substantial increase in NAb titers, suggesting that this vaccine candidate
223 can significantly boost a pre-existing memory response^{47,48}. This is consistent with
224 observations made by Goel et al.⁴⁹ following mRNA vaccination. The increase in NAb titers
225 was greater after the first dose of CoVLP+AS03 (GMT 58.7 → 5458) than the second dose
226 (GMT of 5458 → 7035) suggesting there may be limited additional benefit in providing a

227 second dose to such individuals. These observations provide strong support for vaccinating
228 both infection naïve and previously infected individuals with CoVLP+AS03.

229 Overall, the NAb titers induced by CoVLP+AS03 in both the Adult and Older Adult
230 populations compared well to a panel of convalescent serum/plasma. While this method can be
231 used to draw broad comparisons between studies ^{8,16}, there is a growing consensus that this
232 approach has serious limitations for comparing responses between groups and between trials
233 with different vaccines. For this reason, we included the WHO reference standard 20/136,
234 pooled antibodies from recovered COVID-19 patients with very high NAb response in multiple
235 laboratory studies ⁵⁰ in our serological analysis so that the performance of CoVLP+AS03 can
236 be assessed relative to other vaccines.

237 Although attention on vaccine-induced immune responses for SARS-COV-2 has focused
238 primarily on antibody production, there is compelling evidence that cellular responses
239 contribute to both recovery from infection and long-term immunity ^{14,32}. Despite this growing
240 consensus, what constitutes a ‘good’ or ‘desirable’ response is not yet fully understood ⁵¹. In
241 the current study, the mixed Th₁ (IFN- γ) and Th₂ (IL-4) cellular response to CoVLP+AS03
242 was, like the NAb response, entirely consistent with the Phase 1 results. In both age cohorts, an
243 IFN- γ dominated response was observed after the first dose that shifted to include a substantial
244 IL-4 response after the second dose. Even though the IL-4 response increased significantly after
245 the second dose, SFU counts for IFN- γ remained approximately 2-fold higher than those for IL-
246 4. Of course, the limited nature of using only these two ELISpots to assess the pattern of
247 cellular immunity generated by CoVLP+AS03 should be acknowledged.

248 While Th₂-type responses and possible VAED were initially a point of concern in COVID-19
249 vaccine development ^{52,53}, there has since been no evidence of disease enhancement in either
250 animal models or across all of the human trials reported to date, nor any evidence that Th₂
251 responses are associated with VAED ⁵¹. Indeed, it even possible that the Th₂-response induced
252 by CoVLP+AS03 as characterized by IL-4 production, may contribute significantly to the high
253 titers of neutralizing antibody observed in vaccinated subjects through its role in T helper
254 follicular cell involvement, optimal germinal center formation, and B-cell maturation ^{18,54,55}.
255 Such Th₂-driven effects may also contribute to longevity of SARS-CoV-2 specific memory B-
256 cell responses and longer-term immune response ⁵⁶.

257 Unlike the NAb response, both IFN- γ and IL-4 responses in the Older Adults were significantly
258 weaker than those observed in the Adult population even after the second dose suggesting that

259 at least some aspects of the aged immune system cannot be overcome with multiple doses of an
260 AS03-adjuvanted vaccine. Given the clear age-related differences in both the clinical
261 manifestations of COVID-19 and the immune response generated by SARS-COV-2 infection
262 ⁵⁷, it is not surprising that vaccine-induced responses might also differ between younger and
263 older individuals ⁵⁸. Indeed, similar age-related differences in immune responses have been
264 reported for several of the SARS-COV-2 vaccines in development or in use ^{38,59} and age-related
265 differences in vaccine efficacy with some of the deployed vaccines are emerging ⁶⁰⁻⁶². Given
266 the very high NAb titers induced by CoVLP+AS03 across all ages, it is unclear whether or not
267 the *in vitro* differences in cellular responses between younger and older adults will result in
268 clinically relevant differences in protection. Any such differences might only become apparent
269 as the Phase 3 portion of the study progresses and/or with greater time should CoVLP+AS03 be
270 licensed.

271 This study as presented has several obvious limitations. First, the cut-off for data in this
272 interim report was D42 so longer-term safety and immunogenicity results are not yet available.
273 Also, the report does not include Adults with Comorbidities from the Phase 2 study as these
274 data are still being analyzed. Some immunogenicity data, particular for D42 cell-mediated
275 immune responses, have not yet been fully analyzed. Whether or not the NAb induced by
276 CoVLP+AS03 have activity against variants of concern is of obvious interest and these studies
277 are underway. Finally, the limited demographic diversity of the Phase 2 study participants is
278 acknowledged and is primarily a reflection of the demographics of the study sites where the
279 majority of these participants were recruited. The ongoing global Phase 3 efficacy portion of
280 the trial is being conducted on three continents and is expected to provide efficacy results in a
281 highly diverse population.

282 In conclusion, this interim report of our on-going Phase 2/3 study of CoVLP+AS03 confirms
283 that this formulation is well-tolerated and highly immunogenic in healthy adults ≥ 18 years of
284 age. Compared to either a panel of convalescent serum/plasma or the WHO standard serum
285 reagent (20/136), the NAb response induced by CoVLP+AS03 was among the highest reported
286 for any SARS-COV-2 vaccine. Across the broad age range of study participants (18 – 88 years
287 of age), >99% mounted either a strong NAb response, a balanced Th1/Th2-pattern cellular
288 response, or both following two doses of CoVLP+AS03.

289
290

291 **References**

- 292 1 Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N*
293 *Engl J Med* 382, 727-733, doi:10.1056/NEJMoa2001017 (2020).
- 294 2 Guan, W. J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N*
295 *Engl J Med* 382, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
- 296 3 WHO. World Health Organization, WHO Director-General's opening remarks at the
297 media briefing on COVID-19 - 11 March 2020, <[https://www.who.int/dg/speeches/detail/who-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
298 [director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)>
299 (2020).
- 300 4 WHO. WHO Coronavirus Disease (COVID-19) Dashboard, <<https://covid19.who.int/>>
301 (2021).
- 302 5 Craven, J. COVID-19 vaccine tracker, <[https://www.raps.org/news-and-articles/news-](https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker)
303 [articles/2020/3/covid-19-vaccine-tracker](https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker)> (2021).
- 304 6 Funk, C. D., Laferriere, C. & Ardakani, A. Target Product Profile Analysis of COVID-
305 19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective *Viruses* 13
306 (2021).
- 307 7 COVAX. (2021) in Clinical Development and Operations SWAT team.
- 308 8 Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19
309 vaccines. *medRxiv*, 2021.2003.2017.20200246, doi:10.1101/2021.03.17.20200246 (2021).
- 310 9 Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening
311 COVID-19. *Science* 370, doi:10.1126/science.abd4585 (2020).
- 312 10 De Mot, L. et al. Transcriptional profiles of adjuvanted hepatitis B vaccines display
313 variable interindividual homogeneity but a shared core signature. *Sci Transl Med* 12,
314 doi:10.1126/scitranslmed.aay8618 (2020).
- 315 11 Sobolev, O. et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures
316 of age-dependent early responses and of clinical adverse events. *Nature Immunology* 17, 204-
317 213, doi:10.1038/ni.3328 (2016).
- 318 12 Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening
319 COVID-19. *Science* 370, doi:10.1126/science.abd4570 (2020).

- 320 13 Bloch, E. M. et al. Deployment of convalescent plasma for the prevention and
321 treatment of COVID-19. *J Clin Invest* 130, 2757-2765, doi:10.1172/jci138745 (2020).
- 322 14 McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques.
323 *Nature*, doi:10.1038/s41586-020-03041-6 (2020).
- 324 15 Simonovich, V. A. et al. A Randomized Trial of Convalescent Plasma in Covid-19
325 Severe Pneumonia. *N Engl J Med* 384, 619-629, doi:10.1056/NEJMoa2031304 (2021).
- 326 16 Khoury, D. S. et al. What level of neutralising antibody protects from COVID-19?
327 medRxiv, 2021.2003.2009.21252641, doi:10.1101/2021.03.09.21252641 (2021).
- 328 17 Zuo, J. et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months
329 following primary infection. *Nat Immunol* 22, 620-626, doi:10.1038/s41590-021-00902-8
330 (2021).
- 331 18 Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates
332 with rapid viral clearance and mild disease in COVID-19 patients. *Cell Rep* 34, 108728,
333 doi:10.1016/j.celrep.2021.108728 (2021).
- 334 19 Kalimuddin, S. et al. Early T cell and binding antibody responses are associated with
335 Covid-19 RNA vaccine efficacy onset. *Med (N Y)*, doi:10.1016/j.medj.2021.04.003 (2021).
- 336 20 D'Aoust, M. A. et al. The production of hemagglutinin-based virus-like particles in
337 plants: a rapid, efficient and safe response to pandemic influenza. *Plant Biotechnol J* 8, 607-
338 619, doi:10.1111/j.1467-7652.2009.00496.x (2010).
- 339 21 Ward, B. J. et al. Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine
340 for Covid-19 Disease Produced in Plants. medRxiv, 2020.2011.2004.20226282,
341 doi:10.1101/2020.11.04.20226282 (2020).
- 342 22 Garçon, N., Vaughn, D. W. & Didierlaurent, A. M. Development and evaluation of
343 AS03, an Adjuvant System containing α -tocopherol and squalene in an oil-in-water emulsion.
344 *Expert Rev Vaccines* 11, 349-366, doi:10.1586/erv.11.192 (2012).
- 345 23 Givord, C. et al. Activation of the endoplasmic reticulum stress sensor IRE1 α by the
346 vaccine adjuvant AS03 contributes to its immunostimulatory properties. *npj Vaccines* 3, 20,
347 doi:10.1038/s41541-018-0058-4 (2018).

- 348 24 Morel, S. et al. Adjuvant System AS03 containing α -tocopherol modulates innate
349 immune response and leads to improved adaptive immunity. *Vaccine* 29, 2461-2473,
350 doi:10.1016/j.vaccine.2011.01.011 (2011).
- 351 25 Burny, W. et al. Different Adjuvants Induce Common Innate Pathways That Are
352 Associated with Enhanced Adaptive Responses against a Model Antigen in Humans. *Front*
353 *Immunol* 8, 943, doi:10.3389/fimmu.2017.00943 (2017).
- 354 26 Howard, L. M. et al. AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates
355 Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells. *J Infect Dis*
356 219, 1786-1798, doi:10.1093/infdis/jiy721 (2019).
- 357 27 Khurana, S. et al. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and
358 affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype
359 neutralization. *npj Vaccines* 3, 40, doi:10.1038/s41541-018-0076-2 (2018).
- 360 28 Moris, P. et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-
361 reactive and polyfunctional CD4 T-cell responses. *J Clin Immunol* 31, 443-454,
362 doi:10.1007/s10875-010-9490-6 (2011).
- 363 29 Leroux-Roels, I. et al. Antigen sparing and cross-reactive immunity with an adjuvanted
364 rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. *Lancet* 370, 580-
365 589, doi:10.1016/s0140-6736(07)61297-5 (2007).
- 366 30 Cohet, C. et al. Safety of AS03-adjuvanted influenza vaccines: A review of the
367 evidence. *Vaccine* 37, 3006-3021, doi:10.1016/j.vaccine.2019.04.048 (2019).
- 368 31 Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans
369 with COVID-19 Disease and Unexposed Individuals. *Cell* 181, 1489-1501.e1415,
370 doi:10.1016/j.cell.2020.05.015 (2020).
- 371 32 Sette, A. & Crotty, S. Pre-existing immunity to SARS-CoV-2: the knowns and
372 unknowns. *Nature Reviews Immunology* 20, 457-458, doi:10.1038/s41577-020-0389-z (2020).
- 373 33 Richmond, P. et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein
374 subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-
375 blind, placebo-controlled trial. *Lancet* 397, 682-694, doi:10.1016/s0140-6736(21)00241-5
376 (2021).

- 377 34 Goepfert, P. A. et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein
378 vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study.
379 medRxiv, 2021.2001.2019.20248611, doi:10.1101/2021.01.19.20248611 (2021).
- 380 35 Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine
381 administered in a prime-boost regimen in young and old adults (COV002): a single-blind,
382 randomised, controlled, phase 2/3 trial. *Lancet* 396, 1979-1993, doi:10.1016/s0140-
383 6736(20)32466-1 (2021).
- 384 36 Sadoff, J. et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against
385 Covid-19. *N Engl J Med*, doi:10.1056/NEJMoa2101544 (2021).
- 386 37 Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based
387 heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised
388 phase 1/2 studies from Russia. *Lancet* 396, 887-897, doi:10.1016/s0140-6736(20)31866-3
389 (2020).
- 390 38 Anderson, E. J. et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273
391 Vaccine in Older Adults. *N Engl J Med* 383, 2427-2438, doi:10.1056/NEJMoa2028436 (2020).
- 392 39 Skowronski, D. M. & De Serres, G. Safety and Efficacy of the BNT162b2 mRNA
393 Covid-19 Vaccine. *N Engl J Med* 384, 1576-1577, doi:10.1056/NEJMc2036242 (2021).
- 394 40 Wu, Z. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2
395 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind,
396 placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis*, doi:10.1016/s1473-
397 3099(20)30987-7 (2021).
- 398 41 Xia, S. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,
399 BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect*
400 *Dis* 21, 39-51, doi:10.1016/s1473-3099(20)30831-8 (2021).
- 401 42 Formica, N. et al. Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger
402 and Older Adults. medRxiv, 2021.2002.2026.21252482, doi:10.1101/2021.02.26.21252482
403 (2021).
- 404 43 Müller, L. et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2
405 COVID-19 vaccination. medRxiv, 2021.2003.2003.21251066,
406 doi:10.1101/2021.03.03.21251066 (2021).

- 407 44 Soiza, R. L., Scicluna, C. & Thomson, E. C. Efficacy and safety of COVID-19
408 vaccines in older people. *Age and Ageing* 50, 279-283, doi:10.1093/ageing/afaa274 (2020).
- 409 45 Dugan, H. L., Henry, C. & Wilson, P. C. Aging and influenza vaccine-induced
410 immunity. *Cell Immunol* 348, 103998, doi:10.1016/j.cellimm.2019.103998 (2020).
- 411 46 Del Giudice, G., Rappuoli, R. & Didierlaurent, A. M. Correlates of adjuvanticity: A
412 review on adjuvants in licensed vaccines. *Semin Immunol* 39, 14-21,
413 doi:10.1016/j.smim.2018.05.001 (2018).
- 414 47 Prendecki, M. et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell
415 responses to single-dose BNT162b2 vaccine. *Lancet* 397, 1178-1181, doi:10.1016/s0140-
416 6736(21)00502-x (2021).
- 417 48 Manisty, C. et al. Antibody response to first BNT162b2 dose in previously SARS-
418 CoV-2-infected individuals. *Lancet (London, England)* 397, 1057-1058, doi:10.1016/S0140-
419 6736(21)00501-8 (2021).
- 420 49 Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2
421 naïve and recovered individuals following mRNA vaccination. *Sci Immunol* 6,
422 doi:10.1126/sciimmunol.abi6950 (2021).
- 423 50 Mattiuzzo, G. et al. Establishment of the WHO International Standard and Reference
424 Panel for anti-SARS-CoV-2 antibody. World Health Organization (2020).
- 425 51 Poland, G. A., Ovsyannikova, I. G., Crooke, S. N. & Kennedy, R. B. SARS-CoV-2
426 Vaccine Development: Current Status. *Mayo Clin Proc* 95, 2172-2188,
427 doi:10.1016/j.mayocp.2020.07.021 (2020).
- 428 52 Acosta, P. L., Caballero, M. T. & Polack, F. P. Brief History and Characterization of
429 Enhanced Respiratory Syncytial Virus Disease. *Clin Vaccine Immunol* 23, 189-195,
430 doi:10.1128/cvi.00609-15 (2015).
- 431 53 Lambert, P. H. et al. Consensus summary report for CEPI/BC March 12-13, 2020
432 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. *Vaccine* 38,
433 4783-4791, doi:10.1016/j.vaccine.2020.05.064 (2020).
- 434 54 Cox, R. J. & Brokstad, K. A. Not just antibodies: B cells and T cells mediate immunity
435 to COVID-19. *Nature Reviews Immunology* 20, 581-582, doi:10.1038/s41577-020-00436-4
436 (2020).

- 437 55 Crotty, S. Follicular helper CD4 T cells (TFH). *Annu Rev Immunol* 29, 621-663,
438 doi:10.1146/annurev-immunol-031210-101400 (2011).
- 439 56 Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months
440 after infection. *Science* 371, eabf4063, doi:10.1126/science.abf4063 (2021).
- 441 57 Wong, L. S. Y. et al. Age-Related Differences in Immunological Responses to SARS-
442 CoV-2. *J Allergy Clin Immunol Pract* 8, 3251-3258, doi:10.1016/j.jaip.2020.08.026 (2020).
- 443 58 Cunha, L. L., Perazzio, S. F., Azzi, J., Cravedi, P. & Riella, L. V. Remodeling of the
444 Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19
445 Immune Response. *Front Immunol* 11, 1748, doi:10.3389/fimmu.2020.01748 (2020).
- 446 59 Collier, D. A. et al. Age-related heterogeneity in immune responses to SARS-CoV-2
447 vaccine BNT162b2. *medRxiv*, 2021.2002.2003.21251054, doi:10.1101/2021.02.03.21251054
448 (2021).
- 449 60 Britton, A. et al. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among
450 Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut,
451 December 2020-February 2021. *MMWR Morb Mortal Wkly Rep* 70, 396-401,
452 doi:10.15585/mmwr.mm7011e3 (2021).
- 453 61 Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N*
454 *Engl J Med* 384, 403-416, doi:10.1056/NEJMoa2035389 (2021).
- 455 62 Bernal, J. L. et al. Early effectiveness of COVID-19 vaccination with BNT162b2
456 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease,
457 hospitalisations and mortality in older adults in England. *medRxiv*, 2021.2003.2001.21252652,
458 doi:10.1101/2021.03.01.21252652 (2021).
- 459

460 ***Author Contributions***

461 All authors contributed significantly to the submitted work. BJ Ward, N Landry, A Seguin
462 contributed to all aspects of the clinical study from conception to completion. P Gobeil, A.
463 Mahmood, S Pillet, I Boulay, N Charland contributed to design and execution of the study as
464 well as analysis and presentation of the data. F. Roman, R. Van Der Most, M de los Angeles
465 Ceregido Perez contributed to analysis and presentation of data. MP Cheng provided access to
466 critical reagents and consulted on study design and execution. All authors contributed to critical
467 review of the data and the writing of the manuscript. All Medicago authors had full access to
468 the data. BJW and NL made the final decision to submit the manuscript.

469

470 **Acknowledgements**

471 The authors would like to acknowledge Karyne Framand with support identifying appropriate
472 references. The authors acknowledge Dr Matthew P Cheng (Research institute of the McGill
473 University Health Centre) for supplying convalescent plasma samples from hospitalized Covid
474 patients. The authors also wish to acknowledge all the Medicago employees, their contractors
475 and all the volunteers who participated in the study as well as the site investigators and their
476 staff who conducted the studies with a high degree of professionalism.

477

478 **Funding Statement**

479 The study was sponsored by Medicago Inc.

480

481 **Data Availability**

482 Medicago Inc. is committed to providing access to anonymized data collected during the trial
483 that underlie the results reported in this article, at the end of the clinical trial, which is currently
484 scheduled to be 1 year after the last participant is enrolled, unless granted an extension.
485 Medicago Inc. will collaborate with its partners (GlaxoSmithKline, Rixensart, Belgium) on
486 such requests before disclosure. Proposals should be directed to wardb@medicago.com or
487 landryn@medicago.com. To gain access, data requestors will need to sign a data access
488 agreement and access will be granted for non-commercial research purposes only. The

489 following publicly-available databases were accessed to complete this work: GISAID database
490 (<https://www.gisaid.org/>) and Genbank (<https://www.ncbi.nlm.nih.gov/genbank/>).

491

492 **Conflict of Interest**

493 P. Gobeil, S. Pillet, A. Séguin, I. Boulay, A. Mahmood, N. Charland, B. Ward, and N. Landry
494 are either employees of Medicago Inc or receive salary support from Medicago Inc. P. Boutet,
495 F. Roman, R. Van Der Most, and M. de los Angeles Ceregido Perez are employees of
496 GlaxoSmithKline.

497

498 **Complete File**

499 Abstract (280 words)

500 Text (7746 words)

501 Figures (4)

502 Tables (1)

503 **Figure Legends**

504 **Figure 1**

505 **Trial Profile – Subject Disposition**

506 Enrollment and follow-up of study participants vaccinated with CoVLP with AS03 or placebo
507 after the first and second dose administration. For both Adults and Older Adults one subject
508 was misdosed for the second dose administration and received a placebo in error. For more
509 details of subject disposition, see Table 1.

510 **Figure 2**

511 **Solicited Local and Systemic Adverse Events 7 Days After the First or Second Vaccine**

512 **Candidate Dose**

513 Subjects were monitored for solicited local (panel A) and systemic (panel B) AEs from the time
514 of vaccination through 7 days after administration of each dose. No Grade 4 (potentially life-
515 threatening) events were reported. Participants who reported no adverse events (AEs) make up
516 the remainder of the 100% calculation (not shown). If any of the solicited AEs persisted
517 beyond Day 7 after each vaccination (when applicable), it was recorded as an unsolicited AE.
518 Fever was defined as oral temperature $\geq 38.0^{\circ}\text{C}$.

519 **Figure 3**

520 **Humoral Response in Adults Aged 18-64 and Older Adults Aged 65+**

521 Virus neutralization titers at baseline (Day 0) and 21 days after the first (Day 21) or the second
522 dose (Day 42) of CoVLP +AS03 or placebo. Bars and numerical values indicate geometric
523 means and error bars indicate 95% CI. Significant differences between Days 0, 21 and 42 are
524 indicated by # ($^{###}p < 0.001$; paired T-test of log-transformed values, GraphPad Prism, v9.0).
525 Significant differences across study populations are indicated by * ($^{*}p < 0.05$; Adults vs Older
526 Adults, one-way ANOVA on log-transformed data for GMT). The figure is based on a data
527 cut-off of April 9th.

528 **Figure 4**

529 **Cellular Immune Response in Adults Aged 18-64 and Older Adults Aged 65+**

530 IFN- γ and IL-4 ELISpot Responses. IFN- γ (A) and IL-4 (B) spot forming cell (SFC) counts at
531 baseline (Day 0), 21 days after the first immunization (Day 21) and 21 days after the second
532 immunization (Day 42) with CoVLP (3.75 μg) adjuvanted with AS03 or placebo are
533 represented. Bars indicate median (\pm 95% CI). Results of statistical analysis are represented for
534 relevant comparisons. Significant differences between time-points for each vaccine regimen are

535 indicated by # (### $p < 0.001$; Wilcoxon signed rank test, SAS). Significant differences between
536 study populations at each time-point are indicated by * (** $p < 0.001$; Mann Whitney test,
537 GraphPad Prism v9.0.1). Both IFN- γ and IL-4 responses in subjects injected with placebo were
538 significantly lower (not represented, Wilcoxon rank sum test, SAS) than subjects who received
539 the adjuvanted CoVLP at both Day 21 and Day 42 regardless of the population cohort. An
540 arbitrary value of 0.5 SPC was assigned to samples with undetectable values to allow for
541 representation on a logarithmic scale.

542

543 **Methods**

544 *CoVLP Vaccine Candidate and Adjuvant*

545 The CoVLP vaccine candidate has previously been described in detail ²¹. Briefly, full-length
546 spike protein from SARS-CoV-2 (strain hCoV-19/USA/CA2/2020) incorporating the
547 modifications R667G, R668S, R670S, K971P, and V972P is expressed in *Nicotiana*
548 *benthamiana* by transient transfection, resulting in spontaneous trimer formation and VLP
549 assembly and budding. The VLPs are purified and shipped to the vaccination site where it is
550 mixed with AS03 adjuvant prior to injection.

551 AS03 adjuvant, an oil-in-water emulsion containing DL- α -tocopherol (11.69 mg/dose) and
552 squalene (10.86 mg/dose), was supplied by GlaxoSmithKline.

553 *Vaccine Preparation and Injection*

554 CoVLP was available in single-dose vials (0.30 mL) at 15 μ g/ml and stored at 2-8°C until
555 shortly before use. The AS03 adjuvant was supplied in multi-dose vials (10 doses/vial)
556 containing DL- α -tocopherol (53.76 mg/mL) and squalene (43.44 mg/mL). Immediately prior
557 to use 0.3 mL of CoVLP and 0.3 mL of AS03 were mixed gently 1:1 volume: volume in the
558 CoVLP vial and a 0.5 mL withdrawn for injection. All injections were administered
559 intramuscularly using a 23g needle in the deltoid. The first and second doses were administered
560 contralaterally when possible.

561 *Study Design*

562 The phase 2 portion of the study is a randomized, observer-blinded, placebo-controlled study
563 with male and female subjects. The study was approved by a central Research Ethics Review
564 Board (Advarra 372 Hollandview Trail, Suite 300, Aurora, ON L4G 0A5 Canada) as well as
565 the Health Products and Food Branch of Health Canada and was carried out in accordance with
566 the Declaration of Helsinki and the principles of Good Clinical Practices. Written informed
567 consent was obtained from all study participants prior to any study procedure. Subjects were
568 offered modest compensation for their participation in this study (ie: time off work,
569 displacement costs).

570 Subjects were screened up to 14 days in advance of the first vaccine administration and must
571 have demonstrated a satisfactory baseline medical assessment by history, general physical
572 examination, hematologic, biochemic, and serologic analysis. Although a test for SARS-CoV-2
573 antibodies was performed at screening using a commercial ELISA that targets the nucleocapsid

574 (N) protein (ElecSys: Roche Diagnostics), both seronegative and seropositive subjects were
575 enrolled.

576 For Population 1 (Adults), subjects had to be 18-64 years of age. For Population 2 (Older
577 Adults), subjects had to be 65 years of age or older and to be non-institutionalized (eg, not
578 living in rehabilitation centers or old-age homes; living in an elderly community was
579 acceptable).

580 For both study population presented, subjects must have had a body mass index less than 30
581 kg/m² and be in good general health with no clinically relevant abnormalities that could
582 jeopardize subject safety or interfere with study assessments, as determined by medical history,
583 physical examination, and vital signs. Investigator discretion was permitted with this inclusion
584 criterion. Female subjects of childbearing potential had to have a negative serum pregnancy test
585 result at screening and/or a negative urine pregnancy test result at vaccination. Additional
586 exclusion criteria included i) any significant acute or chronic, uncontrolled medical or
587 neuropsychiatric illness, ii) any chronic medical condition associated with elevated risk of
588 severe outcome of COVID-19 including obesity, diabetes (type 1 or type 2), significant
589 cardiovascular or respiratory diseases including asthma, chronic renal failure, disorders of
590 bleeding/coagulation, chronic inflammatory or autoimmune conditions, immunosuppressive
591 conditions (including HIV), and hypertension, iii) any confirmed or suspected current
592 immunosuppressive condition or immunodeficiency, including cancer, HIV, hepatitis B or C
593 infection, iv) current autoimmune disease, v) administration of any medication or treatment that
594 could alter the vaccine immune response, vi) administration of any vaccine within 14 days prior
595 to vaccination or planned administration of any vaccine up to Day 28 of the study, vii)
596 administration of any other SARS-CoV-2 / COVID-19, or other experimental coronavirus
597 vaccine at any time prior to or during the study, viii) history of virologically-confirmed
598 COVID-19, ix) a rash, dermatological condition, tattoos, muscle mass, or any other
599 abnormalities at injection site that could interfere with injection site reaction rating, x) use of
600 prophylactic medications (eg, antihistamines [H1 receptor antagonists], nonsteroidal anti-
601 inflammatory drugs [NSAIDs], systemic and topical glucocorticoids, non-opioid and opioid
602 analgesics) within 24 hours prior to the Vaccination, xi) history of a serious allergic response to
603 any of the constituents of CoVLP including AS03, xii) history of documented anaphylactic
604 reaction to plants or plant components (including tobacco, fruits and nuts), xiii) personal or
605 family (first-degree relatives) history of narcolepsy, xiv) a history of Guillain-Barré Syndrome.

606 Enrollment into the Phase 2 portion of the study was closed on 25 March 2021.

607 The participants and the personnel collecting the safety information and working in testing
608 laboratories remained blinded to treatment allocation. On Day 0, D21 and D42, serum and
609 peripheral blood mononuclear cells (PBMC) were processed for immune outcomes. All safety
610 information was collected, and all laboratory procedures were carried out by study staff blinded
611 to treatment allocation. There were no major Protocol changes during the conduct of this study
612 prior to the preparation of the current manuscript.

613 *Primary and Secondary Objectives:*

614 The primary objectives of the Phase 2 portion of the study were to assess safety and tolerability
615 and immunogenicity to CoVLP and AS03 at day 0, 21, and 42 post vaccination compared to
616 placebo in Adults and Older Adults.

617 Primary safety outcomes were the occurrence(s) of i) immediate AEs within 30 minutes after
618 each vaccination; ii) solicited local and systemic AEs up to 7 days after each vaccination; iii)
619 unsolicited AEs, serious AEs (SAEs), AEs leading to withdrawal, AEs of special interest
620 (AESIs), and deaths up to 21 days after each vaccination; iv) normal and abnormal urine,
621 haematological, and biochemical values.

622 Primary immunogenicity outcomes were i) neutralizing antibody (NAb) titers measured using a
623 pseudovirion neutralization assays and ii) interferon (IFN)- γ and IL-4 ELISpot responses at 21
624 days after each dose of vaccine.

625 Secondary objectives were to assess the immunogenicity in study populations at days 128, 201
626 and 386 post-vaccination.

627 A secondary safety outcome was the occurrence(s) of SAEs, AEs leading to withdrawal,
628 AESIs, and deaths from 22 days after the last vaccination up to the end of the study that is still
629 on-going. Secondary immunogenicity outcomes were immune responses measured at days 128,
630 201 and 386 post-vaccination.

631 The safety and immunogenicity data collected at later timepoints in this on-going study will be
632 released once study follow-up has been completed.

633 *Safety Assessments*

634 Both passive (diary) and active monitoring of safety signals were performed for the first 42
635 days of the study and will be continued throughout the study. Active monitoring included

636 telephone contacts with subjects one and eight days (D1, D8) after each vaccination as well as a
637 site visit on D3 after vaccination. Solicited AEs were assessed by the subjects as Grade 1 to 4
638 (mild, moderate, severe, or potentially life-threatening) according to the criteria previously
639 described ²¹. Unsolicited AEs, and AEs leading to subject withdrawal were collected up to D21
640 after each vaccination. The following event(s) would pause or halt the study for further review
641 and assessment of the event(s) by the IDMC: i) Any death, ii) Any vaccine-related SAE; iii)
642 Any life-threatening (Grade 4) vaccine-related AE; iv) If 10 % or more of subjects in a single
643 treatment group, experienced the same or similar listed event(s) that could not be clearly
644 attributed to another cause: v) A severe (Grade 3 or higher) vaccine-related AE; vi) A severe
645 (Grade 3 or higher) vaccine-related vital sign(s) abnormality; vii) A severe (Grade 3 or higher)
646 vaccine-related clinical laboratory abnormality.

647 In the event that a pre-defined safety signal was met in any treatment group, at least a transient
648 halt to the study was planned to permit complete evaluation of the reported event(s) and to
649 consult with the IDMC.

650 Subjects will return to the Investigator site on Days 128, 201, and 386 for safety follow-ups and
651 immunogenicity assessments.

652 Safety signals for VAED, hypersensitivity reactions, and potential immune-mediated diseases
653 were monitored as previously described ²¹.

654 *SARS-CoV-2 Pseudovirus Immunogenicity- Neutralisation Assay*

655 Full details of the pseudovirus neutralization assay (Nexelis, Quebec, Canada) have previously
656 been described ²¹. Briefly, the assay is based on a genetically modified Vesicular Stomatitis
657 Virus (VSV) from which the glycoprotein G was removed, and a luciferase reporter introduced.
658 The modified VSV vector expresses full length SARS-CoV-2 S glycoprotein (NXL137-1 in
659 POG2 containing 2019-nCoV Wuhan-Hu-1; Genebank: MN908947) from which the last
660 nineteen amino acids of the cytoplasmic tail were removed (rVSVΔG-Luc-Spike ΔCT).
661 Pseudovirions are mixed with vaccinee sera and the degree of neutralization quantified using
662 human ACE-2 expressing VERO cells and reduction in luciferase-based luminescence. For
663 each sample, the neutralizing titer was defined as the reciprocal dilution corresponding to the
664 50% neutralization (NT₅₀), when compared to the pseudoparticle control. Samples below cut-
665 off were attributed a value of 5 (half the minimum required dilution).

666 To facilitate the comparability of results across different trials, the WHO International Standard
667 for anti-SARS-CoV-2 immunoglobulin (human; NIBSC code: 20/136) was established to allow
668 conversion of neutralization assay titers into international units (IU/mL). This standard consists
669 of pooled plasma obtained from eleven individuals recovered from SARS-CoV-2 infection.
670 Upon multiple assessments using this validated PNA assay, a conversion factor of 1.872 was
671 established. Hence, the antibody titers presented throughout this manuscript can be expressed
672 as IU/mL by dividing the NT50 by this factor.

673 *Immunogenicity- Interferon- γ and Interleukin-4 ELISpot*

674 PBMC samples from study subjects were analyzed by IFN- γ or IL-4 ELISpot (Caprion,
675 Quebec, Canada) using a pool of 15-mer peptides with 11aa overlaps from SARS-CoV-2 S
676 protein (USA-CA2/2020, Genbank: MN994468.1, Genscript, purity >90%). Full details of the
677 methodology are detailed elsewhere ²¹.

678 *Convalescent serum and plasma samples*

679 Sera/plasma from COVID-19 convalescent patients were collected from a total of 35
680 individuals with confirmed disease diagnosis. Time between the onset of the symptoms and
681 sample collection varied between 27 and 105 days. Four sera samples were collected by
682 Solomon Park (Burien, WA, USA) and 20 sera samples by Sanguine BioSciences (Sherman
683 Oaks, CA, USA); all were from non-hospitalized individuals. Eleven plasma samples were
684 collected from previously hospitalized patients at McGill University Health Centre. Disease
685 severity were ranked as mild (COVID-19 symptoms without shortness of breath), moderate
686 (shortness of breath reported), and severe (hospitalized). These samples were analysed in
687 parallel of clinical study samples, using the assays described above. Demographic
688 characteristics were previously described in Ward et al. ²¹.

689 *Analysis Populations and Statistical Analysis Plan*

690 Randomization was managed by Syneos Health with Medicago oversight using Medidata Rave
691 RTSM interactive randomization tool (2021.2.0, Medidata, USA). The sample size of 306
692 vaccinated Adults and 282 Older Adults made it possible to perform the initial evaluation of the
693 vaccine immunogenicity and detect major differences in rates of AEs between groups. The
694 sample size was not large enough to detect all types of, including less frequent or rare, AEs.
695 With 494 subjects receiving the CoVLP formulation, there was at least 95% probability of
696 observing an AE that occurs as frequently as 1 in 165 vaccinees. The analyses of all

697 immunogenicity endpoints were performed using the Intent-to-Treat population set (ITT). The
698 ITT consists of all randomized subjects who received the CoVLP and AS03 or placebo and
699 analyzed prior to the data cut (Adults: Day 21 n=299; Day 42 n=299; Older Adults Day 21
700 n=255; Day 42 n=165). Immunogenicity was evaluated by humoral immune response (NtAb
701 assays) and cell-mediated immune (CMI) response (ELISpot) induced in subjects on D0, 21
702 and 42. To assess the humoral immune response, the GMT was calculated and compared
703 between CoVLP and AS03 and placebo using an ANOVA on the log-transformed titers. The
704 log transformation was used to meet the normal assumption for the ANOVA. At each
705 timepoint, the GMT and corresponding 95% CI of each treatment were obtained by exponential
706 back-transformation of the least square mean. GMT were compared between Adults and Older
707 Adults at Day 21 and Day 42 using an ANOVA. Fisher's exact test was used to compare
708 seroconversion rate between the treatment groups. The 95% CI for seroconversion was
709 calculated using the exact Clopper-Pearson method. The specific T helper type 1 (Th1) and Th2
710 CMI responses along with the corresponding 95% CI for the median induced on D0, D21 and
711 D42 were measured by the number of T cells expressing IFN- γ and IL-4 respectively, using
712 ELISpot. The difference in IFN- γ and IL-4 response between treatment group at each timepoint
713 was compared using a non-parametric Wilcoxon Rank Sum Test. Since the response between
714 timepoints are paired data, the Wilcoxon Signed Rank Test was used to estimate the difference
715 in response between timepoints, along with the corresponding 95% CI for the median
716 separately for each treatment group. The difference in IFN- γ and IL-4 were also compared
717 between Adults and Older Adults at Day 21 and Day 42 using a Wilcoxon Rank Sum Test.
718 Safety assessment are based on the Safety Analysis Set, i.e. all subjects who received either the
719 CoVLP candidate vaccine with or without an adjuvant. Occurrence and incidence of safety
720 events were reported for each treatment groups. No formal hypothesis-testing analysis of AE
721 incidence rates was performed, and results were not corrected for multiple comparisons.

722 **TABLE**

723 **Table 1: Summary of demographics and baseline characteristics (NCT04636697)**

	Adults		Older Adults	
	CoVLP 3.75 µg +AS03	Placebo	CoVLP 3.75 µg +AS03	Placebo
Subjects	259	47	235	47
Sex, n (%)				
Male	112 (43.2)	23 (48.9)	110 (46.8)	19 (40.4)
Female	147 (56.8)	24 (51.1)	125 (53.2)	28 (59.6)
Race, n (%)				
American Indian or Alaska Native	0	0	1 (0.4)	0
Asian	5 (1.9)	1 (2.1)	3 (1.3)	0
Black or African American	2 (0.8)	1 (2.1)	0	0
Native Hawaiian or Other Pacific Islander	0	0	0	0
White or Caucasian	251 (96.9)	45 (95.7)	231 (98.3)	47 (100)
Not Reported	1 (0.4)	0	0	0
Age at the time of informed consent (years)				
Mean (SD)	43.7 (13.00)	42.4 (13.29)	71.1 (5.14)	71.7 (4.87)
Median	45.0	45.0	70.0	72.0
Min, Max	18, 64	18, 64	65, 88	65, 87
SARS-CoV-2 at Baseline, n (%)				
Positive	8 (3.1)	0	5 (2.1)	1 (2.1)
Negative	247 (95.4)	46 (97.9)	225 (95.7)	46 (97.9)


724 Max, maximum; Min, minimum; n, number of subjects in categories; SD, standard deviation.

725

726 **FIGURES**

727 **Figure 1**


728



729


730 **Figure 2**

A. Solicited Local Reactions



731

B. Solicited Systemic Reactions




732

733 **Figure 3 Humoral Response in Adults Aged 18-64 and Older Adults Aged 65+**

734

735



736


737

738

739 **Figure 4**


740

A



741

B



742